Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
Affiliation
University Hospitals Coventry and Warwickshire NHS Trust; University of Wolverhampton; Coventry University; University of Chester; Sowe Valley Primary Care Network; National and Kapodistrian University of Athens; Aston University; University of Derby; Agricultural University of AthensPublication Date
2024-05-29Metadata
Show full item recordAbstract
The prevalence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing worldwide, making it the leading cause of liver related morbidity and mortality. Currently, liver biopsy is the gold standard for assessing individuals with steatohepatitis and fibrosis. However, its invasiveness, sampling variability, and impracticality for large-scale screening has driven the search for non-invasive methods for early diagnosis and staging. In this review, we comprehensively summarise the evidence on the diagnostic performance and limitations of existing non-invasive serum biomarkers and scores in the diagnosis and evaluation of steatosis, steatohepatitis, and fibrosis. Several non-invasive serum biomarkers and scores have been developed over the last decade, although none has successfully been able to replace liver biopsy. The introduction of new NAFLD terminology, namely metabolic dysfunction-associated fatty liver disease (MAFLD) and more recently metabolic dysfunction-associated steatotic liver disease (MASLD), has initiated a debate on the interchangeability of these terminologies. Indeed, there is a need for more research on the variability of the performance of non-invasive serum biomarkers and scores across the diagnostic entities of NAFLD, MAFLD and MASLD. There remains a significant need for finding valid and reliable non-invasive methods for early diagnosis and assessment of steatohepatitis and fibrosis to facilitate prompt risk stratification and management to prevent disease progression and complications. Further exploration of the landscape of MASLD under the newly defined disease subtypes is warranted, with the need for more robust evidence to support the use of commonly used serum scores against the new MASLD criteria and validation of previously developed scores. [Abstract copyright: © 2024. The Author(s).]Citation
Abdelhameed, F., Kite, C., Lagojda, L., Dallaway, A., Chatha, K. K., Chaggar, S. S., Dalamaga, M., Kassi, E., Kyrou, I., & Randeva, H. S. (2024). Non-invasive scores and serum biomarkers for fatty liver in the era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A comprehensive review From NAFLD to MAFLD and MASLD. Current obesity Reports, 13, 510–531. https://doi.org/10.1007/s13679-024-00574-zPublisher
SpringerJournal
Current Obesity ReportsAdditional Links
https://link.springer.com/article/10.1007/s13679-024-00574-zType
ArticleDescription
The version of record of this article, first published in [Current Obesity Reports], is available online at Publisher’s website: http://dx.doi.org/10.1007/s13679-024-00574-zISSN
2162-4968Sponsors
UnfundedScopus Count
Collections
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/
Related items
Showing items related by title, author, creator and subject.
-
Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN studyNon-alcoholic steatohepatitis (NASH) leads to cirrhosis and is associated with a substantial socioeconomic burden, which, coupled with rising prevalence, is a growing public health challenge. However, there are few real-world data available describing the impact of NASH. The Global Assessment of the Impact of NASH (GAIN) study is a prevalence-based burden of illness study across Europe (France, Germany, Italy, Spain, and the UK) and the USA. Physicians provided demographic, clinical, and economic patient information via an online survey. In total, 3,754 patients found to have NASH on liver biopsy were stratified by fibrosis score and by biomarkers as either early or advanced fibrosis. Per-patient costs were estimated using national unit price data and extrapolated to the population level to calculate the economic burden. Of the patients, 767 (20%) provided information on indirect costs and health-related quality of life using the EuroQOL 5-D (EQ-5D; n = 749) and Chronic Liver Disease Questionnaire - Non-Alcoholic Fatty Liver Disease (CLDQ-NAFLD) (n = 723). Mean EQ-5D and CLDQ-NAFLD index scores were 0.75 and 4.9, respectively. For 2018, the mean total annual per patient cost of NASH was €2,763, €4,917, and €5,509 for direct medical, direct non-medical, and indirect costs, respectively. National per-patient cost was highest in the USA and lowest in France. Costs increased with fibrosis and decompensation, driven by hospitalisation and comorbidities. Indirect costs were driven by work loss. The GAIN study provides real-world data on the direct medical, direct non-medical, and indirect costs associated with NASH, including patient-reported outcomes in Europe and the USA, showing a substantial burden on health services and individuals. There has been little research into the socioeconomic burden associated with non-alcoholic steatohepatitis (NASH). The GAIN study provides real-world data on the direct medical, direct non-medical, and indirect costs associated with NASH, including patient-reported outcomes in five European countries (UK, France, Germany, Spain, and Italy) and the USA. Mean total annual per patient cost of NASH was estimated at €2,763, €4,917, and €5,509 for the direct medical, direct non-medical, and indirect cost categories, respectively. [Abstract copyright: © 2020 The Author(s).]
-
Maternal obesity and metabolic (dysfunction) associated fatty liver disease in pregnancy: a comprehensive narrative reviewIntroduction: Obesity and metabolic-associated fatty liver disease (MAFLD) during pregnancy constitute significant problems for routine antenatal care, with increasing prevalence globally. Similar to obesity, MAFLD is associated with a higher risk for maternal complications (e.g. pre-eclampsia and gestational diabetes) and long-term adverse health outcomes for the offspring. However, MAFLD during pregnancy is often under-recognized, with limited management/treatment options. Areas covered: PubMed/MEDLINE, EMBASE, and Scopus were searched based on a search strategy for obesity and/or MAFLD in pregnancy to identify relevant papers up to 2024. This review summarizes the pertinent evidence on the relationship between maternal obesity and MAFLD during pregnancy. Key mechanisms implicated in the underlying pathophysiology linking obesity and MAFLD during pregnancy (e.g. insulin resistance and dysregulated adipokine secretion) are highlighted. Moreover, a diagnostic approach for MAFLD diagnosis during pregnancy and its complications are presented. Finally, promising relevant areas for future research are covered. Expert opinion: Research progress regarding maternal obesity, MAFLD, and their impact on maternal and fetal/offspring health is expected to improve the relevant diagnostic methods and lead to novel treatments. Thus, routine practice could apply more personalized management strategies, incorporating individualized algorithms with genetic and/or multi-biomarker profiling to guide prevention, early diagnosis, and treatment.
-
Too many calories, Refined carbohydrates, and saturated fat Consumption endow to Nonalcoholic Fatty Liver Disease in Pakistani AdultsNonalcoholic Fatty Liver Disease (NAFLD) is one of the leading causes of liver disease worldwide. A healthy diet plays a significant role in the prevention of NAFLD. Few studies have been done in Pakistan to evaluate the dietary intake of patients suffering from NAFLD. This study aimed to look into the dietary intake of NAFLD patients being treated at a tertiary care hospital in Karachi, Pakistan Objective: To determine the nutritional status of NAFLD patients. Method: 118 NAFLD patients, aged 18 to 60, male and female, were enrolled. Patients with advanced liver or kidney failure, decompensated liver disease, hepatocellular carcinoma, acute flare, and chronic liver disease were excluded. This cross-sectional study used an interview-administered questionnaire to collect data on sociodemographic characteristics, anthropometric measurements, nutrition-related biochemical measurements, and dietary intake (24-hour diet recall and validated food frequency questionnaire). Data were analyzed using SPSS (VERSION) Statistics v26 RESULTS: Out of 118 subjects; 69% were female, Anthropometric data revealed that 41% were morbidly obese (BMI 29 >kg/m2). The average daily calorie and protein intakes were 2135 kcal and 64.2 gm, respectively. Dietary recall indicates a high consumption of saturated fat foods including paratha (34%), cake (16.9%), pizza (17.8%), banaspati ghee (11%), and consumption of high glycemic fruits like Mango (42%) and dates (32.2%). Practical implication: this study will benefit that healthy diet plays a significant role prevention of NAFLD,and can reduce the burden of obesity and its complication in later life. Low carbohydrate intake, limiting saturated fat and increased physical activity play a vital role in management of NAFLD CONCLUSION: Participants with NAFLD had insufficient dietary patterns. This may be associated with lower consumption of fruits and vegetables, and increased intake of high saturated fat and glycemic index foods; behavioral strategies should be implemented to change this patient's overall dietary intake.
